MCRB – Seres Therapeutics, Inc.
Float Short %
13.96
Margin Of Safety %
Put/Call OI Ratio
0.18
EPS Next Q Diff
-2.94
EPS Last/This Y
0.77
EPS This/Next Y
-11.2
Price
16.66
Target Price
21
Analyst Recom
2
Performance Q
-27.09
Relative Volume
0.4
Beta
0.21
Ticker: MCRB
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | MCRB | 14.04 | 0.12 | 0.00 | 12912 |
| 2025-11-11 | MCRB | 14.77 | 0.12 | 0.28 | 13141 |
| 2025-11-12 | MCRB | 16.24 | 0.12 | 0.02 | 13245 |
| 2025-11-13 | MCRB | 16.85 | 0.13 | 0.00 | 13304 |
| 2025-11-14 | MCRB | 16.74 | 0.13 | 0.00 | 13314 |
| 2025-11-17 | MCRB | 21.46 | 0.13 | 0.00 | 13356 |
| 2025-11-18 | MCRB | 24.76 | 0.12 | 0.12 | 13864 |
| 2025-11-19 | MCRB | 28.63 | 0.13 | 0.16 | 13798 |
| 2025-11-20 | MCRB | 21.98 | 0.16 | 0.27 | 13908 |
| 2025-11-21 | MCRB | 17.67 | 0.17 | 0.06 | 15505 |
| 2025-11-24 | MCRB | 16.9 | 0.16 | 0.03 | 12063 |
| 2025-11-25 | MCRB | 16.86 | 0.16 | 0.08 | 12090 |
| 2025-11-26 | MCRB | 16.89 | 0.16 | 0.01 | 12099 |
| 2025-12-01 | MCRB | 17.21 | 0.18 | 0.02 | 12461 |
| 2025-12-02 | MCRB | 16.63 | 0.18 | 0.00 | 12470 |
| 2025-12-03 | MCRB | 17.37 | 0.18 | 0.19 | 12490 |
| 2025-12-04 | MCRB | 17.79 | 0.18 | 2.88 | 12534 |
| 2025-12-05 | MCRB | 16.54 | 0.18 | 0.09 | 12541 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | MCRB | 14.05 | 38.2 | - | 1.34 |
| 2025-11-11 | MCRB | 14.90 | 38.2 | - | 1.34 |
| 2025-11-12 | MCRB | 16.23 | 38.2 | - | 1.34 |
| 2025-11-13 | MCRB | 16.72 | 38.2 | - | 1.34 |
| 2025-11-14 | MCRB | 16.64 | 38.2 | - | 1.34 |
| 2025-11-17 | MCRB | 21.53 | 38.2 | - | 1.34 |
| 2025-11-18 | MCRB | 24.80 | 38.2 | - | 1.34 |
| 2025-11-19 | MCRB | 28.63 | 38.2 | - | 1.34 |
| 2025-11-20 | MCRB | 21.80 | 38.2 | - | 1.34 |
| 2025-11-21 | MCRB | 17.59 | 27.3 | - | 0.77 |
| 2025-11-24 | MCRB | 16.97 | 27.3 | - | 0.77 |
| 2025-11-25 | MCRB | 16.92 | 27.3 | - | 0.77 |
| 2025-11-26 | MCRB | 16.92 | 27.3 | - | 0.77 |
| 2025-12-01 | MCRB | 17.49 | 27.3 | - | 0.77 |
| 2025-12-02 | MCRB | 16.70 | 27.3 | - | 0.77 |
| 2025-12-03 | MCRB | 17.44 | 27.3 | - | 0.77 |
| 2025-12-04 | MCRB | 17.61 | 27.3 | - | 0.77 |
| 2025-12-05 | MCRB | 16.66 | 27.3 | - | 0.77 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | MCRB | -0.04 | -10.08 | 12.10 |
| 2025-11-11 | MCRB | -0.04 | -10.08 | 12.10 |
| 2025-11-12 | MCRB | -0.04 | -10.08 | 14.92 |
| 2025-11-13 | MCRB | -0.04 | -10.08 | 14.92 |
| 2025-11-14 | MCRB | -0.04 | -10.08 | 14.83 |
| 2025-11-17 | MCRB | -0.04 | -9.61 | 14.83 |
| 2025-11-18 | MCRB | -0.14 | -9.61 | 14.83 |
| 2025-11-19 | MCRB | -0.14 | -9.61 | 14.83 |
| 2025-11-20 | MCRB | -0.12 | -9.61 | 14.83 |
| 2025-11-21 | MCRB | -0.12 | -9.61 | 14.83 |
| 2025-11-24 | MCRB | -0.12 | -1.91 | 14.85 |
| 2025-11-25 | MCRB | -0.12 | -1.91 | 14.85 |
| 2025-11-26 | MCRB | -0.12 | -1.91 | 13.96 |
| 2025-12-01 | MCRB | -0.12 | -1.78 | 13.96 |
| 2025-12-02 | MCRB | -0.12 | -1.78 | 13.96 |
| 2025-12-03 | MCRB | -0.12 | -1.78 | 13.96 |
| 2025-12-04 | MCRB | -0.12 | -1.78 | 13.96 |
| 2025-12-05 | MCRB | -0.12 | -1.78 | 13.96 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.94
Avg. EPS Est. Current Quarter
-1.6
Avg. EPS Est. Next Quarter
-2
Insider Transactions
-0.12
Institutional Transactions
-1.78
Beta
0.21
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
9
Growth Score
17
Sentiment Score
72
Actual DrawDown %
97.2
Max Drawdown 5-Year %
-98.8
Target Price
21
P/E
27.44
Forward P/E
PEG
P/S
430.61
P/B
3.34
P/Free Cash Flow
EPS
0.61
Average EPS Est. Cur. Y
0.77
EPS Next Y. (Est.)
-10.43
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
1536.75
Relative Volume
0.4
Return on Equity vs Sector %
-14.6
Return on Equity vs Industry %
0.3
EPS 1 7Days Diff
-0.6
EPS 1 30Days Diff
-0.57
EBIT Estimation
Seres Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 103
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
stock quote shares MCRB – Seres Therapeutics, Inc. Stock Price stock today
news today MCRB – Seres Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MCRB – Seres Therapeutics, Inc. yahoo finance google finance
stock history MCRB – Seres Therapeutics, Inc. invest stock market
stock prices MCRB premarket after hours
ticker MCRB fair value insiders trading